CD8A and lymphoma: Whereas we observed weakened humoral immunity in aCD20 treated lymphoma patients, we also detected a concurrent decrease in T regulatory cells and an increase in Th1 cells and EMRA CD8 + T cells within the vaccine-induced, SARS-CoV-2-specific T cell population.